Enrollment opened today for the MJFF-funded Phase IIa clinical trial to test the safety and tolerability of nilotinib in Parkinson’s disease.

The trial will investigate the potential of repurposing nilotinib (which many in the patient community know is an FDA-approved treatment for cancer of the white blood cells) in Parkinson’s.

Learn more about recruiting sites and eligibility criteria on our website and download our guide on what patients and families should know about repurposed therapies.

Best, Debi